nodom
zakłady farmaceutyczne polpharma s.a. - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide
trusopt
santen oy - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide
trusopt
lex ano, uab - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide
verospiron
gedeon richter plc - spironolaktonas - kietosios kapsulės - 100 mg; 50 mg; 25 mg - spironolactone
cosopt
sia scandic pharma - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
cosopt
limedika, uab - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
zessly
sandoz gmbh - infliksimabas - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresantai - gydymo reumatoidiniu artritu, krono liga, opinis kolitas, ankilozuojantis spondilitas, psoriazinis artritas ir psoriaze.
cosopt sine
santen oy - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.